Business Context and Reporting Period
Company: Synthetic Blood International, Inc. (Note: Metadata listed "Tenax Therapeutics," but filing text confirms "Synthetic Blood International, Inc.")
Reporting Period: Quarterly report (Form 10-Q) for the period ended October 31, 2000.
Status: Development stage company focused on pre-clinical product development. No revenue-generating operations.
Key Financial Metrics
| Metric | Three Months Ended Oct 31, 2000 | Six Months Ended Oct 31, 2000 | As of Oct 31, 2000 |
|---|---|---|---|
| Revenue | $0 | $0 | N/A |
| Net Loss | $(508,450) | $(762,133) | Accumulated Deficit: $(12,075,471) |
| Operating Expenses | $599,783 | $944,401 | N/A |
| Cash and Equivalents | N/A | N/A | $5,099,191 |
| Working Capital | N/A | N/A | $4,846,034 |
| Debt | N/A | N/A | Current Notes Payable: $0 |
| Shares Outstanding | N/A | N/A | 87,353,436 |
Material Changes vs. Prior Period
- Expense Growth: Total expenses for the three months ended Oct 31, 2000, increased to $599,783 from $203,576 in the prior year period.
- Research & Development: Rose to $175,197 (from $26,545) due to new lab employees, a new California facility, and increased equipment depreciation.
- General & Administrative: Rose to $424,324 (from $174,252) driven by stock-based compensation for consultants ($112,298), investor expenses ($53,000), and market research ($38,000).
- Net Loss: Increased to $508,450 for the quarter (from $178,216) and $762,133 for the six-month period (from $398,573). The loss increase was partially offset by higher interest income on cash balances.
- Cash Flow: Net cash used in operating activities was $569,440 for the six months ended Oct 31, 2000, compared to $290,475 in the prior year. Financing activities provided $407,504, primarily from stock sales.
Outlook, Risks, and Management Commentary
- Liquidity: Management believes current cash ($5.1M) is sufficient for operations for the next 24 months. Excess cash is invested in short-term money market instruments.
- Capital Needs: Significant additional financing is required for further development, testing, and potential FDA clinical trials. No firm commitments for future capital exist as of Oct 31, 2000.
- Risks:
- Failure to achieve results in pre-clinical studies or obtain FDA approval.
- Inability to secure strategic partnerships or financing, which could force delays or elimination of product programs.
- Patent uncertainties and potential infringement risks.
- Manufacturing scaling difficulties and market acceptance risks.
- Corporate Actions: Shareholders approved amendments to the Certificate of Incorporation (authorizing preferred stock, lowering amendment voting thresholds) and a new 1999 Stock Plan authorizing 4 million shares.
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of the $5.1M cash balance against the projected 24-month runway given the accelerating expense growth.
- Financing Commitments: Confirm if any strategic alliances or financing commitments have been secured since the filing date to fund Phase II trials.
- Dilution Risk: Assess the impact of the newly authorized 4 million share stock plan and potential future equity raises on existing shareholder ownership.
- Regulatory Milestones: Monitor progress of pre-clinical studies required for FDA approval to initiate clinical trials.
- Stock Issuances: Review the valuation and terms of recent stock issuances for services and cash to ensure fair market value compliance.